Synergistic Antibiotic Activity and Integrated Genomic-Metabolomic Profiling of Patch - and Plaque -Derived Staphylococcus aureus in Mycosis Fungoides

This study reveals that *Staphylococcus aureus* isolates from advanced mycosis fungoides lesions exhibit distinct genomic and metabolomic adaptations linked to increased virulence and resistance compared to those from early lesions, while identifying synergistic antibiotic combinations as effective strategies to target these multidrug-resistant strains.

The Gist

The Big Picture: A Skin Battle Gone Wrong

Imagine your skin is a bustling city. In a healthy city, different neighborhoods (bacteria) live in harmony. But in patients with Mycosis Fungoides (MF), a type of skin cancer, the city is under siege. The "good guys" are pushed out, and a notorious gangster bacterium called Staphylococcus aureus (Staph) takes over the streets.

This isn't just any Staph; it's a "super-bug" that has learned to ignore most of the police (antibiotics) we usually send in. The researchers wanted to understand two things:

1. How does this bad guy get so tough and smart as the disease gets worse?
2. Can we trick him into dying by using a team of antibiotics instead of just one?

---

Part 1: The "Patch" vs. The "Plaque" (Early vs. Late Stage)

The researchers looked at Staph bacteria taken from two different types of skin lesions:

• Patches: These are the early, flat, itchy red spots. Think of these as the "suburbs" of the skin city.
• Plaques: These are the advanced, thick, raised, and angry-looking lesions. Think of these as the "fortified castle" in the city center.

The Discovery:
The bacteria living in the Plaques (the advanced stage) were much more dangerous than those in the Patches.

• The Patch Bacteria: They were like street fighters. They had lots of weapons designed to fight other bacteria (like a Type VII secretion system, which is like a bacterial spear gun used to kill neighbors). They were focused on winning a turf war against other microbes.
• The Plaque Bacteria: They had evolved into "hostile invaders." They dropped the weapons meant for other bacteria and picked up a massive arsenal designed to fight you (the human host). They had more "stealth cloaks" to hide from your immune system, more "toxins" to poison your cells, and a much bigger "resistance shield" against antibiotics.

The Analogy:
Imagine the bacteria in the early stage are like bikers fighting over a parking spot. They are aggressive, but they are mostly fighting each other.
By the time they reach the advanced stage (the Plaque), they have transformed into special forces soldiers. They have stopped fighting each other and are now fully focused on invading the castle (your body), wearing heavy armor (resistance) and carrying heavy artillery (toxins).

---

Part 2: The "Key and Lock" Problem (Antibiotic Resistance)

The bacteria in the advanced plaques were Multidrug-Resistant.

• The Problem: If you try to kill them with one antibiotic (like a single key), the bacteria just lock the door. They have so many "locks" (resistance genes) that the key doesn't fit.
• The Solution: The researchers tried a new strategy: Synergy. Instead of using one key, they tried using two keys at the same time to jam the lock.

The Winning Combo:
They found that mixing Carbenicillin (a beta-lactam antibiotic) with either Gentamicin or Levofloxacin worked like magic.

• How it worked: It's like sending a battering ram (Carbenicillin) to break the door down, while a ninja (Gentamicin/Levofloxacin) slips inside to take out the guards. Even the toughest "super-bugs" that could survive the battering ram alone were defeated when the ninja joined the team.
• The Result: This combination restored the ability to kill the bacteria, even the ones that were previously impossible to treat.

---

Part 3: The "ID Card" and "Fingerprint" (Genomics and Metabolomics)

To understand why the bacteria changed, the scientists looked at their genetic code (their ID card) and their chemical waste products (their fingerprints).

• The Genetic ID: The advanced bacteria had a "shopping list" of dangerous genes that the early bacteria didn't have. They had extra genes for:
  • Immune Evasion: A "cloaking device" to hide from your white blood cells.
  • Stress Response: A "survival kit" to handle heat, acid, and antibiotics.
  • Toxins: More poison to damage your skin.
• The Chemical Fingerprint: The bacteria in the advanced stage were also producing different chemicals.
  • Some chemicals helped them build biofilms (a sticky slime fortress that protects them).
  • One specific chemical, Urocanic acid, was interesting. Usually, this is a moisturizer in your skin, but the bacteria were making it in a way that might actually dampen your immune system, making it easier for the cancer and the bacteria to grow together.

---

The Takeaway: What Does This Mean for Patients?

1. The Enemy Evolves: As Mycosis Fungoides gets worse, the bacteria living on the skin don't just stay the same; they get smarter, tougher, and more focused on attacking the host. They shift from fighting neighbors to fighting the patient.
2. Teamwork Wins: Using a single antibiotic is often like trying to stop a tank with a water pistol. This study shows that combining antibiotics (like Carbenicillin + Gentamicin) is a much better strategy. It breaks the bacteria's defenses and offers a new hope for treating these difficult infections.
3. Future Hope: By understanding exactly how these bacteria change, doctors can develop better treatments that target the specific "superpowers" the bacteria gain in the later stages of the disease.

In short: The bacteria are changing their strategy as the disease progresses, but by using a "tag-team" approach with antibiotics, we might finally be able to beat them.

Technical Summary

1. Problem Statement

Mycosis Fungoides (MF), the most common form of cutaneous T-cell lymphoma, is frequently complicated by skin dysbiosis dominated by multidrug-resistant (MDR) Staphylococcus aureus. High colonization by S. aureus correlates with increased disease severity, pain, and accelerated progression from early-stage patches to advanced plaques and tumors. The pathogen's enterotoxins are suspected of driving T-cell polarization and inflammation, exacerbating the lymphoma. However, there is a critical lack of:

• Effective therapeutic strategies for MDR S. aureus in MF patients.
• Molecular understanding of how S. aureus adapts to different stages of MF (patch vs. plaque) to drive disease progression.

2. Methodology

The study employed an integrated multi-omics approach combined with phenotypic antibiotic testing:

• Sample Collection & Isolation: Skin swabs were collected from MF patients at the University Medical Centre Mainz, targeting lesional (patches and plaques) and non-lesional skin. Isolates were identified via tuf-gene PCR and Sanger sequencing.
• Phenotypic Characterization:
  • Antibiotic Susceptibility: Disk diffusion assays and Minimum Inhibitory Concentration (MIC) determinations were performed for various antibiotics (β-lactams, aminoglycosides, fluoroquinolones).
  • Synergy Testing: Checkerboard assays were used to calculate Fractional Inhibitory Concentration (FIC) indices for antibiotic combinations (e.g., Carbenicillin + Gentamicin/Levofloxacin).
  • Biofilm Assays: Quantification of biofilm formation under sub-MIC antibiotic exposure.
• Genomic Analysis:
  • Whole Genome Sequencing (WGS): Illumina short-read sequencing (2x250 bp) was performed on isolates.
  • Bioinformatics: Assemblies were scaffolded (MeDuSa), annotated (Prokka), and analyzed for:
    • Antibiotic Resistance Genes (ARGs) using CARD, ResFinder, MEGARes, and AMRFinderPlus.
    • Virulence factors (VFDB) and Pathogenicity Islands (IslandViewer, PHASTER).
    • Secondary Metabolite Biosynthetic Clusters (antiSMASH).
    • Comparative genomics (MUMmer4) to identify genomic islands and gene presence/absence.
• Metabolomic Profiling:
  • GC-MS: Gas Chromatography-Mass Spectrometry was used to analyze supernatants from bacterial cultures to identify strain-specific metabolic signatures.

3. Key Contributions

• Identification of Synergistic Therapeutics: The study identifies specific antibiotic combinations capable of overcoming high-level resistance in MF-associated S. aureus, particularly for strains resistant to monotherapy.
• Stage-Specific Adaptation Model: It establishes a clear genomic and metabolic divergence between S. aureus isolated from early-stage (patch) versus advanced-stage (plaque) MF lesions.
• Mechanistic Insight into Progression: The work links specific virulence repertoires (e.g., expanded enterotoxins, immune evasion factors) and metabolic shifts to the transition from patch to plaque, suggesting a mechanism for how bacterial adaptation may drive MF progression.

4. Key Results

A. Antibiotic Resistance and Synergy

• Resistance Profiles: All MF-derived isolates were resistant to β-lactams. Plaque-derived isolates (MFMZ1, MFMZ4-1, MFMZ4-3) exhibited broader resistance profiles (including gentamicin, levofloxacin, and tetracycline) compared to patch/non-lesional isolates.
• Synergistic Combinations:
  • Carbenicillin + Gentamicin/Levofloxacin: These combinations showed strong synergy (FIC ≤ 0.5), significantly reducing MICs even in highly resistant strains like MFMZ4-3 (which was resistant to carbenicillin and kanamycin alone).
  • Ampicillin + Gentamicin: Despite ampicillin showing no activity alone, the combination restored potent synergy against resistant strains.
  • Biofilm: Sub-MIC carbenicillin induced biofilm formation in some strains, highlighting the risk of sub-optimal dosing.

B. Genomic Divergence (Patch vs. Plaque)

• Virulence Repertoire: Plaque-derived isolates possessed expanded virulence gene sets, including:
  • Enterotoxins/Superantigens: Higher abundance of sec, sei, sem, sep and superantigen-like proteins.
  • Immune Evasion: Presence of sak (staphylokinase), scn (complement inhibitor), and sdrD.
  • Stress Adaptation: Enrichment of GroES/EL and Clp protease clusters, aiding survival in the fluctuating MF skin microenvironment.
• T7SS (Type VII Secretion System):
  • Patch Isolates: Retained extensive T7SS loci (e.g., essG), associated with interbacterial competition.
  • Plaque Isolates: Showed a reduction in T7SS effector genes but an enrichment of TIGR-TAS (Tandem Interspaced Guide RNA-associated proteins) immunity systems within the T7SS locus. This suggests a shift from competing with other bacteria to defending against mobile genetic elements and adapting to the host.
• Resistance Genes: Plaque isolates harbored significantly more ARGs (60–61 genes) compared to patch isolates (43–46 genes), correlating positively with total virulence gene counts (Spearman ρ = 0.67).

C. Metabolomic Signatures

• Strain-Specific Metabolites:
  • Plaque Isolates: Produced metabolites linked to host interaction and inflammation, such as urocanic acid (potentially immunosuppressive upon UV conversion) and 2,3-butanediol (stress resistance).
  • Patch Isolates: Showed profiles consistent with ecological competition.
  • Putrescine: Uniquely detected in MFMZ4-1, associated with biofilm stability and acid stress response.

5. Significance and Conclusion

This study provides a comprehensive framework for understanding the progressive adaptation of S. aureus in Mycosis Fungoides. The findings suggest a biological shift where early-stage colonization relies on interbacterial competition (T7SS dominance), while advanced-stage colonization prioritizes host immune evasion, stress tolerance, and toxin production (expanded virulence/resistome).

Clinical Implications:

1. Therapeutic Strategy: The identification of synergistic antibiotic combinations (specifically Carbenicillin with Gentamicin or Levofloxacin) offers a viable treatment avenue for MDR S. aureus in MF patients where standard monotherapies fail.
2. Disease Monitoring: The distinct genomic and metabolic signatures of plaque-derived isolates could serve as biomarkers for disease progression or targets for anti-virulence therapies.
3. Future Directions: The study underscores the need to target bacterial adaptation mechanisms (e.g., stress response systems) and highlights the potential of immunomodulatory strategies to counteract the immunosuppressive effects of bacterial metabolites like urocanic acid.